News

AgroSpheres Named on Both the World’s Top GreenTech Companies 2025 and America’s Top GreenTech Companies 2025 Lists by TIME Magazine

AgroSpheres has been named on both the World’s Top GreenTech Companies 2025 and America’s Top GreenTech Companies 2025 lists. These prestigious awards are presented by TIME and Statista Inc., the leading statistics portal and industry ranking provider. The award lists were announced on March 25th, 2025, and can be viewed on TIME’s website.

Statista ranked the winners based on three evaluation criteria:

  • Positive environmental impact: The scoring is based on impact data such as the quality and impact of their product/service portfolio, as well as the expertise of their leadership team provided by HolonIQ
  • Financial strength: The scoring is based on the analysis of financial data points e.g., revenue, employee or funding information
  • Innovation drive: The scoring is based on the Patent Asset Index featured in LexisNexis® Intellectual Property Solutions

“Being recognized by TIME as one of the top GreenTech companies in both the U.S. and globally is a testament to the power of science-driven innovation in reshaping agriculture and our strong business fundamentals,” said Payam Pourtaheri, Co-Founder and CEO of AgroSpheres. “We have built a solid financial foundation to support the rapid commercialization of our bio-based solutions, ensuring long-term impact for growers and the environment. This recognition reinforces our mission to lead the way in the bio-based revolution.”

“Innovation drive and impact go hand in hand,” added Ameer Shakeel, AgroSpheres’ Co-Founder and CTO. “We have built an end-to-end technology platform, rooted in cutting-edge science, novel active ingredients and a strong intellectual property portfolio. Our advancements in encapsulation and delivery technologies are paving the way for greener, more effective crop protection solutions across the industry. As we scale our operations to commercialization, this honor from TIME highlights the growing momentum behind sustainable agriculture worldwide.”

In support of the research, Statista gathered data from company applications, annual reports, media monitoring, and other public sources. Additionally, Statista worked with specialized data partners HolonIQ and LexisNexis® Intellectual Property Solutions to further strengthen the data quality.

Statista publishes hundreds of worldwide industry rankings and company listings with high-profile media partners. This research and analysis service is based on the success of statista.com, the leading data and business intelligence portal that provides statistics, relevant business data, and various market and consumer studies and surveys.

Read more here.

Recent News

06/02/2025

Virginia Tech researchers find promise in a new peptide drug to combat a deadly brain cancer

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech’s Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer. In a study published May 16 in Cell Death and Disease, researchers identified a previously unknown trait of cancer cells that

05/28/2025

Brandy Salmon named Virginia Tech’s first vice president for innovation and partnerships

Brandy Salmon, who since 2017 has led Virginia Tech teams focused on connecting the university with corporations, foundations, and alumni worldwide has been named the university’s first vice president for innovation and partnerships. “True collaboration between higher education, government, and industry is essential for success in today’s evolving landscape,” said Virginia Tech President Tim Sands.

05/28/2025

Avera Joins Civica to Help Minimize Risk of Drug Shortages

Civica, a nonprofit pharmaceutical company created to prevent and mitigate drug shortages, announced today that Avera, a leading nonprofit healthcare provider in the Upper Midwest United States, has joined the company in helping protect patients from the impact of drug shortages of essential generic sterile injectable medicines. Drug shortages are a persistent challenge to the